FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995118081> ?p ?o ?g. }

• W1995118081 endingPage "54" @default.
• W1995118081 startingPage "46" @default.
• W1995118081 abstract "The primary objective of this study was to evaluate the outcome of patients treated with high-dose chemo-/radiotherapy or high-dose chemotherapy and autologous stem-cell transplant (ASCT) for relapsed, refractory, or poor-risk intermediate-grade (IG) and high-grade (HG) non-Hodgkin's lymphoma (NHL). The secondary objectives were to determine prognostic factors for relapse and survival. Between February 1987 and August 1998, 264 patients, 169 (64%) IG and 95 (36%) HG, underwent high-dose therapy and ASCT at City of Hope National Medical Center (COHNMC). There were 157 (59%) males and 107 (41%) females with a median age of 44 years (range, 5-69 years). The median number of prior chemotherapy regimens was 2 (range, 1-4), and 71 (27%) had received prior radiation as part of induction or as salvage therapy. The median time from diagnosis to ASCT was 10.8 months (range, 3-158 months). Ninety-four patients (36%) underwent transplantation in first complete/partial remission (CR/PR), 40 (15%) in induction failure, and 130 (49%) in relapse or subsequent remission. Two preparative regimens were used: total body irradiation/high-dose etoposide/cyclophosphamide (TBI/VP/CY) in 208 patients (79%) and carmustine/etoposide/cyclophosphamide (BCNU/VP/CY) in 56 patients (21%). One hundred sixty-three patients (62%) received peripheral blood stem cells (PBSC) and 101 (38%) received bone marrow (BM) alone or BM plus PBSC. At a median follow-up of 4.43 years for surviving patients (range, 1-12.8 years), the 5-year Kaplan-Meier estimates of probability of overall survival (OS), progression-free survival (PFS), and relapse for all patients are 55% (95% confidence interval [CI]: 49%-61%), 47% (95% CI: 40%-53%), and 47% (95% CI: 40%-54%), respectively. There were 27 deaths (10%) from nonrelapse mortality, including seven (3%) patients who developed second malignancies (five with myelodysplasia/acute myelogenous leukemia and two with solid tumors). By stepwise Cox regression analysis, disease status at ASCT was the only prognostic factor that predicted for both relapse and survival. The 5-year probability of PFS for patients transplanted in first CR/PR was 73% (95% CI: 62%-81%) as compared to 30% (95% CI: 16%-45%) for induction failure and 34% (95% CI: 26%-42%) for relapsed patients. Our results further support the role of high-dose therapy and ASCT during first CR/PR for patients with poor-risk intermediate- and high-grade NHL. Early transplant is recommended for patients failing initial induction therapy or relapsing after chemotherapy-induced remission. Relapse continues to be the most common cause of treatment failure. An alternative approach to prevent relapse, the incorporation of radioimmunotherapy into the high-dose regimen, is being investigated. The development of a second malignancy is a serious complication of high-dose therapy, which requires close surveillance." @default.
• W1995118081 created "2016-06-24" @default.
• W1995118081 creator A5004337476 @default.
• W1995118081 creator A5011178245 @default.
• W1995118081 creator A5020684790 @default.
• W1995118081 creator A5023917993 @default.
• W1995118081 creator A5032471863 @default.
• W1995118081 creator A5034400547 @default.
• W1995118081 creator A5035985145 @default.
• W1995118081 creator A5037972294 @default.
• W1995118081 creator A5039374832 @default.
• W1995118081 creator A5043320174 @default.
• W1995118081 creator A5046784402 @default.
• W1995118081 creator A5052032114 @default.
• W1995118081 creator A5052651941 @default.
• W1995118081 creator A5057798024 @default.
• W1995118081 creator A5058365130 @default.
• W1995118081 creator A5059734562 @default.
• W1995118081 creator A5071631687 @default.
• W1995118081 creator A5073784584 @default.
• W1995118081 creator A5074606840 @default.
• W1995118081 creator A5075376684 @default.
• W1995118081 creator A5075930791 @default.
• W1995118081 creator A5089688977 @default.
• W1995118081 creator A5091818686 @default.
• W1995118081 date "2000-06-01" @default.
• W1995118081 modified "2023-10-17" @default.
• W1995118081 title "Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma" @default.
• W1995118081 cites W1497143314 @default.
• W1995118081 cites W1544519462 @default.
• W1995118081 cites W1807744984 @default.
• W1995118081 cites W1819949687 @default.
• W1995118081 cites W1822252547 @default.
• W1995118081 cites W1877303819 @default.
• W1995118081 cites W1888347784 @default.
• W1995118081 cites W1903601656 @default.
• W1995118081 cites W1937538988 @default.
• W1995118081 cites W1997353354 @default.
• W1995118081 cites W2135157531 @default.
• W1995118081 cites W2139401596 @default.
• W1995118081 cites W2178468906 @default.
• W1995118081 cites W2207262939 @default.
• W1995118081 cites W2229863299 @default.
• W1995118081 cites W2254173625 @default.
• W1995118081 cites W2263814165 @default.
• W1995118081 cites W2267583049 @default.
• W1995118081 cites W2313423582 @default.
• W1995118081 cites W2320751441 @default.
• W1995118081 cites W2395585278 @default.
• W1995118081 cites W254205321 @default.
• W1995118081 cites W4238329799 @default.
• W1995118081 cites W4293241248 @default.
• W1995118081 doi "https://doi.org/10.3816/clm.2000.n.004" @default.
• W1995118081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11707813" @default.
• W1995118081 hasPublicationYear "2000" @default.
• W1995118081 type Work @default.
• W1995118081 sameAs 1995118081 @default.
• W1995118081 citedByCount "51" @default.
• W1995118081 countsByYear W19951180812012 @default.
• W1995118081 countsByYear W19951180812013 @default.
• W1995118081 countsByYear W19951180812015 @default.
• W1995118081 countsByYear W19951180812016 @default.
• W1995118081 countsByYear W19951180812017 @default.
• W1995118081 countsByYear W19951180812021 @default.
• W1995118081 crossrefType "journal-article" @default.
• W1995118081 hasAuthorship W1995118081A5004337476 @default.
• W1995118081 hasAuthorship W1995118081A5011178245 @default.
• W1995118081 hasAuthorship W1995118081A5020684790 @default.
• W1995118081 hasAuthorship W1995118081A5023917993 @default.
• W1995118081 hasAuthorship W1995118081A5032471863 @default.
• W1995118081 hasAuthorship W1995118081A5034400547 @default.
• W1995118081 hasAuthorship W1995118081A5035985145 @default.
• W1995118081 hasAuthorship W1995118081A5037972294 @default.
• W1995118081 hasAuthorship W1995118081A5039374832 @default.
• W1995118081 hasAuthorship W1995118081A5043320174 @default.
• W1995118081 hasAuthorship W1995118081A5046784402 @default.
• W1995118081 hasAuthorship W1995118081A5052032114 @default.
• W1995118081 hasAuthorship W1995118081A5052651941 @default.
• W1995118081 hasAuthorship W1995118081A5057798024 @default.
• W1995118081 hasAuthorship W1995118081A5058365130 @default.
• W1995118081 hasAuthorship W1995118081A5059734562 @default.
• W1995118081 hasAuthorship W1995118081A5071631687 @default.
• W1995118081 hasAuthorship W1995118081A5073784584 @default.
• W1995118081 hasAuthorship W1995118081A5074606840 @default.
• W1995118081 hasAuthorship W1995118081A5075376684 @default.
• W1995118081 hasAuthorship W1995118081A5075930791 @default.
• W1995118081 hasAuthorship W1995118081A5089688977 @default.
• W1995118081 hasAuthorship W1995118081A5091818686 @default.
• W1995118081 hasConcept C126322002 @default.
• W1995118081 hasConcept C141071460 @default.
• W1995118081 hasConcept C2776694085 @default.
• W1995118081 hasConcept C2776755627 @default.
• W1995118081 hasConcept C2778119113 @default.
• W1995118081 hasConcept C2778880498 @default.
• W1995118081 hasConcept C2779050716 @default.
• W1995118081 hasConcept C2779338263 @default.
• W1995118081 hasConcept C2780147359 @default.
• W1995118081 hasConcept C2911091166 @default.

• next